Status:
TERMINATED
Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin
Lead Sponsor:
Ohio State University
Conditions:
Diabetes Mellitus, Type 2
Patient Discharge
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
Diabetes is present in 25% of hospitalized patients; yet effective hospital discharge programs for patients with diabetes are understudied. In particular, patients who are initiating or intensifying i...
Detailed Description
In this 24 week randomized controlled trial, hospitalized insulin-requiring patients with type 2 diabetes and poor glycemic control (HbA1c \>8.5%) will receive standard of care insulin therapy includi...
Eligibility Criteria
Inclusion
- Diagnosis of diabetes, type 2 ≥3 months duration
- HbA1c \>8.5%
- Ages 25-75 years
- Phone or electronic media availability
- Receiving basal insulin \>10 unit/day
Exclusion
- Sensitive admissions: Prisoners
- Pregnancy
- Unable to consent or follow study directions in English
- Expected nursing facility stay longer than 2 weeks
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2020
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT03455985
Start Date
May 1 2018
End Date
September 11 2020
Last Update
February 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University
Columbus, Ohio, United States, 43210